SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-143465
Filing Date
2023-05-12
Accepted
2023-05-12 16:06:54
Documents
12
Period of Report
2023-05-10
Items
Item 5.07: Submission of Matters to a Vote of Security Holders

Document Format Files

Seq Description Document Type Size
1 8-K d371572d8k.htm   iXBRL 8-K 35839
  Complete submission text file 0001193125-23-143465.txt   154463

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA ngm-20230510.xsd EX-101.SCH 2845
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE ngm-20230510_lab.xml EX-101.LAB 17236
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ngm-20230510_pre.xml EX-101.PRE 10810
6 EXTRACTED XBRL INSTANCE DOCUMENT d371572d8k_htm.xml XML 3296
Mailing Address 333 OYSTER POINT BOULEVARD SOUTH SAN FRANCISCO CA 94080
Business Address 333 OYSTER POINT BOULEVARD SOUTH SAN FRANCISCO CA 94080 650-243-5555
NGM BIOPHARMACEUTICALS INC (Filer) CIK: 0001426332 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38853 | Film No.: 23915657
SIC: 2834 Pharmaceutical Preparations